Testing how a new medicine is absorbed by tumors in patients with advanced lung and neuroendocrine cancers
An Open-label Phase 1 PET Imaging Trial to Investigate [89Zr]Zr-BI 764532 Biodistribution and Tumour Uptake in Patients With Small-cell Lung Carcinoma or Neuroendocrine Carcinoma
This study is testing a new medicine to see how well it gets absorbed by tumors in adults with advanced lung or neuroendocrine cancers who haven't had success with other treatments.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Boehringer Ingelheim Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amsterdam) |
| Trial ID | NCT05963867 on ClinicalTrials.gov |
What this trial studies
This clinical trial is designed for adults with advanced small cell lung cancer or neuroendocrine cancers who have not responded to previous treatments or have no standard treatment options available. Participants will receive a medication called BI 764532, and doctors will monitor how well this drug is taken up by tumors using imaging techniques. The study involves regular visits to assess treatment tolerance and any side effects, with the possibility of extending treatment duration based on individual responses. The goal is to gather data on the drug's distribution in the body and its effectiveness in these challenging cancer types.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced small cell lung cancer or neuroendocrine cancers who have exhausted standard treatment options.
Not a fit: Patients with early-stage cancers or those who have not yet undergone conventional treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with advanced cancers that currently have limited effective therapies.
How similar studies have performed: While this approach is novel in its specific application, similar studies targeting drug absorption in tumors have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Weight ≥ 60kg * Signed and dated, written informed consent form (ICF) in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses. * Patient who failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted available treatment options known to prolong survival for their disease. Previous therapies should include at least one line of platinum-based chemotherapy. Previous therapy with anti Programmed Cell Death Protein 1 (PD-1) or Programmed Cell Death Ligand 1 (PD-L1) are allowed. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * At least one evaluable lesion outside of Central Nervous System (CNS) as defined per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 * Subjects with brain metastases are eligible provided they meet the following criteria: * radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532, * patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant CNS disease. Further inclusion criteria apply. Exclusion Criteria: * Previous or concomitant malignancies other than the one treated in this trial within the last 2 years except: * effectively treated non-melanoma skin cancers * effectively treated carcinoma in situ of the cervix * effectively treated ductal carcinoma in situ * other effectively treated malignancy that is considered cured by local treatment * Major injuries and/or surgery or bone fracture within 28 days of first dose BI 764532, or planned surgical procedures * Known leptomeningeal disease or spinal cord compression due to metastatic disease * Anticoagulant treatment that cannot be safely interrupted based on opinion of the investigator if medically needed * Active infection that requires medical therapy or other clinically significant intervention * Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 2 weeks prior to study entry (confirmed via polymerase chain reaction (PCR) test or other applicable test as per local requirements) or suspected SARS-CoV-2 infection as per physician assessment, or close contact (within 1 week) with an individual with confirmed SARS-CoV-2 infection * Any of the following known laboratory evidence of hepatitis virus infection: * Positive results of hepatitis B surface (HBs) antigen * Presence of hepatitis B core (HBc) antibody together with hepatitis B virus DNA (HBV-DNA) * Presence of hepatitis C ribonucleic acid (RNA) * Known human immunodeficiency virus (HIV) infection. Further exclusion criteria apply.
Where this trial is running
Amsterdam
- Amsterdam UMC Locatie VUMC — Amsterdam, Netherlands (Recruiting)
Study contacts
- Study coordinator: Boehringer Ingelheim
- Email: clintriage.rdg@boehringer-ingelheim.com
- Phone: 1-800-243-0127
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.